
Interested in all things biosecurity, public health, nanotechnology, metascience, space, and more! Trying to prevent pandemics @blueprintbio
Washington, DC
Joined March 2012
- Tweets330
- Following1.6K
- Followers830
- Likes5K
Jacob Swett retweeted
Applications are now open for the 2027 Cohort of Brains Fellows!
If you have an ambitious technical research idea (in any discipline) that is beyond the scope of an academic lab or VC-funded startup, we want to hear from you!
spec.tech/brains
Jacob Swett retweeted
Intercept just published a Request for Candidates for broad-spectrum preventatives. We’re seeking the best ideas that align with our target product concept (in brief: safe, easy to administer, long-acting preventatives that will prevent ≥75% of symptomatic respiratory infections in as few doses as possible).
We’ll prioritize proposals received by October 12, and this call will remain open through at least the end of this year.
Read more below and please share this with any teams who may be interested!
interceptfund.com/apply/broa…
If you're ever curious what the etymology of east or west is in a language, it's likely it's the words for 'sunrise/dawn' or 'sunset/evening':
English: east = dawn, west = evening (from Proto-Indo-European)
Greek: Ανατολή = the rising, Δύση = the setting
Arabic: شرق = to rise, غرب = to set/disappear
Latin: oriēns = rising, occidēns = setting/falling
Hebrew: mizraḥ = place of rising, ma’arav = place of setting
The pattern is remarkably widespread. Swahili borrowed from Arabic. It’s found across all Germanic languages and many Semitic, Turkic, Austronesian, and Mayan languages. Even the modern Romance words for east and west ultimately derive from Germanic words meaning “dawn” and “evening”!
Jacob Swett retweeted
After writing a private blog on philanthropic craft since early 2025, I'll now share those reflections with you all
First piece is on bringing a monomaniacal focus to a single problem and fully owning it.
I've felt firsthand the unreasonable effectiveness of putting on the blinders until my job is done – yet it stays criminally underrated in nonprofit & philanthropy worlds. Scopes tend to creep; I chalk it up to culture, incentives, and misapplications of Swiss-cheese thinking.
Good news is that you don't have to succumb to any of these!
Jacob Swett retweeted
In a hotel room in northeast Nigeria, I opened a leading AI chatbot, turned my laptop toward a former Boko Haram commander, and asked if he'd used it. He nodded.
"You type in the question… like 'How can I build a bomb?', and then it tells you how. It is like a human robot. We used it a lot."
My new study on how the jihadist terrorist group Boko Haram uses frontier AI with @CamAISciPolicy, covered today in @nytimes 🧵/9
2025's death rate (age-adjusted all-cause mortality) in the US was the lowest ever recorded, which is incredible progress, but influenza and pneumonia are now in the top 10 - fortunately, there is a lot in the pipeline to push this number down!
Jacob Swett retweeted
You've heard of far-UVC light for sanitizing against airborne pathogens, but have you heard of glycol vapors? (TIL)
blueprintbiosecurity.org/pro…
Thrilled that we'll hopefully get a new version of this figure before too long!
Today we're launching Intercept: a $500M philanthropic initiative to make respiratory infections, like the common cold and flu, a thing of the past.
We treat respiratory infections as a minor nuisance, but that’s really not the case. Most of us will spend 5% of our lives (!) sick from these viruses, they kill 1M people a year, cost $600B annually in productivity, and periodically threaten civilization through pandemics.
So, if they’re such a big problem, why haven’t we dealt with them yet? Last year we convened ~40 leading scientists, pharma R&D leaders, biotech investors, and regulatory experts to better understand that.
We heard two main reasons:
(1) First, it’s just technically very challenging: respiratory viruses represent hundreds of distinct, mutating strains across several families. Fortunately, recent breakthroughs make this newly possible.
(2) Second is a lack of funding: broad-spectrum solutions have historically been underfunded, in part because they’re not a great fit for most philanthropic or commercial funding (and while COVID generated a burst of activity around preventing and understanding respiratory infections through an influx of new funding, that hasn't been sustained).
We think that with enough focus and funding, this might be solvable. Intercept is a $500 million philanthropic initiative that will take advantage of new tools to catalyze the development and deployment of two types of products: broad-spectrum preventatives and air cleaning technologies.
This problem is undoubtedly difficult. But it’s more tractable now than it’s ever been. We think we should give it our best shot.
We’re enormously grateful to our anchor funders: @stripe, @AnthropicAI, @TheFluLab, @FoundationOAI and individuals from Jane Street.
And, I’m very excited to be building this with @incredutility and the rest of the team.
Jacob Swett retweeted
New project: interceptfund.com.
More: interceptfund.substack.com/p….
Jacob Swett retweeted
I joined @Stripe in January to build a new philanthropic initiative with @nanransohoff. Today we’re announcing Intercept, a $500m innovation fund focused on radically reducing the burden of respiratory viruses.
I’ve spent the past decade investing in vaccines and drugs for infectious disease, and this is the most exciting thing I’ve ever been a part of. Thrilled to be working with @Stripe, @AnthropicAI, @TheFluLab, @FoundationOAI, @coeff_giving and individuals from Jane Street.
We've raised the capital and now it’s time to get to work.
Today we're launching Intercept: a $500M philanthropic initiative to make respiratory infections, like the common cold and flu, a thing of the past.
We treat respiratory infections as a minor nuisance, but that’s really not the case. Most of us will spend 5% of our lives (!) sick from these viruses, they kill 1M people a year, cost $600B annually in productivity, and periodically threaten civilization through pandemics.
So, if they’re such a big problem, why haven’t we dealt with them yet? Last year we convened ~40 leading scientists, pharma R&D leaders, biotech investors, and regulatory experts to better understand that.
We heard two main reasons:
(1) First, it’s just technically very challenging: respiratory viruses represent hundreds of distinct, mutating strains across several families. Fortunately, recent breakthroughs make this newly possible.
(2) Second is a lack of funding: broad-spectrum solutions have historically been underfunded, in part because they’re not a great fit for most philanthropic or commercial funding (and while COVID generated a burst of activity around preventing and understanding respiratory infections through an influx of new funding, that hasn't been sustained).
We think that with enough focus and funding, this might be solvable. Intercept is a $500 million philanthropic initiative that will take advantage of new tools to catalyze the development and deployment of two types of products: broad-spectrum preventatives and air cleaning technologies.
This problem is undoubtedly difficult. But it’s more tractable now than it’s ever been. We think we should give it our best shot.
We’re enormously grateful to our anchor funders: @stripe, @AnthropicAI, @TheFluLab, @FoundationOAI and individuals from Jane Street.
And, I’m very excited to be building this with @incredutility and the rest of the team.
Jacob Swett retweeted
It’s great to see AI leaders like Sam Altman, Dario Amodei, and Demis Hassabis calling for mandatory DNA synthesis screening, which is a no-brainer policy for preventing (AI-enabled) bioterrorism.
But fewer than 50 people in the world currently work on DNA security full-time.
We need a comprehensive plan and at least 5x as many people to secure the DNA supply chain before AI and biotech outpace us.
@jtmonrad and I spent the past two years developing a field strategy for how to do it.
Successfully defending against this risk (while still capturing innovation benefits) requires four things:
1. Coverage: More than 80% of synthetic DNA providers screen both orders and customers
2. Strategic ambiguity: a bad actor can’t easily tell which providers will screen their order
3. Access: legitimate customers can still order DNA cheaply and easily
4. Effectiveness: 90% of providers reliably catch dangerous sequences when red-teamed
We’re already seeing real momentum. Many DNA providers screen voluntarily, and governments in several countries are moving toward mandates. But that doesn’t mean the problem will be solved in time by default.
Our guide lays out exactly which projects we need to launch. We’re looking for founders, operators, and technical experts to own pieces of the solution. We’re also hiring a Senior Program Officer at Sentinel to drive this work. Get in touch if you or someone you know would be a strong fit! (links for EOI form and JD below)
Read our full field strategy in @IFP's Launch Sequence: ifp.org/how-to-secure-the-dn…
No one should be able to order a bioweapon through the mail.
@IFP & @JoinFAI are proud to co-lead an open letter calling for mandatory DNA synthesis screening & recordkeeping.
Signatories include:
- Sam Altman, CEO & Co-Founder, OpenAI
- Dario Amodei, CEO & Co-Founder, Anthropic
- David Baker, Director, Institute for Protein Design; 2024 Nobel Prize in Chemistry recipient
- Patrick Collison, CEO & Co-Founder, Stripe
- Paul Graham, Founder, Y Combinator
- Demis Hassabis, CEO, Google DeepMind; 2024 Nobel Prize in Chemistry recipient
- Emily Leproust, CEO & Co-Founder, Twist Bioscience
- Lawrence Lessig, Roy L. Furman Professor of Law and Leadership, Harvard Law School
- Gerald W. Parker, former Special Assistant to the President for Biosecurity and Pandemic Response
- Mustafa Suleyman, CEO, Microsoft AI
- Alex Tabarrok, Professor of Economics, George Mason University
- Alexandr Wang, Chief AI Officer, Meta; Founder, Scale AI
- Christine E. Wormuth, President & CEO, Nuclear Threat Initiative; 25th Secretary of the Army
Read the letter and see the full list of signatories: screendna.org
Many DNA synthesis companies voluntarily screen orders to mitigate biosecurity risks, but no law requires them to do so.
Leaders in AI, biotech, life sciences, national security, and the nucleic acid synthesis industry agree that Congress should act to strengthen safeguards against biological threats.
@deanwball put it well in the WSJ:
“If you’re synthesizing the stuff that yields biological life and viruses, we’re asking you to screen to see whether it is dangerous in some way. That seems like a reasonable thing for society to insist upon.”
Jacob Swett retweeted
No one should be able to order a bioweapon through the mail.
@IFP & @JoinFAI are proud to co-lead an open letter calling for mandatory DNA synthesis screening & recordkeeping.
Signatories include:
- Sam Altman, CEO & Co-Founder, OpenAI
- Dario Amodei, CEO & Co-Founder, Anthropic
- David Baker, Director, Institute for Protein Design; 2024 Nobel Prize in Chemistry recipient
- Patrick Collison, CEO & Co-Founder, Stripe
- Paul Graham, Founder, Y Combinator
- Demis Hassabis, CEO, Google DeepMind; 2024 Nobel Prize in Chemistry recipient
- Emily Leproust, CEO & Co-Founder, Twist Bioscience
- Lawrence Lessig, Roy L. Furman Professor of Law and Leadership, Harvard Law School
- Gerald W. Parker, former Special Assistant to the President for Biosecurity and Pandemic Response
- Mustafa Suleyman, CEO, Microsoft AI
- Alex Tabarrok, Professor of Economics, George Mason University
- Alexandr Wang, Chief AI Officer, Meta; Founder, Scale AI
- Christine E. Wormuth, President & CEO, Nuclear Threat Initiative; 25th Secretary of the Army
Read the letter and see the full list of signatories: screendna.org
Many DNA synthesis companies voluntarily screen orders to mitigate biosecurity risks, but no law requires them to do so.
Leaders in AI, biotech, life sciences, national security, and the nucleic acid synthesis industry agree that Congress should act to strengthen safeguards against biological threats.
@deanwball put it well in the WSJ:
“If you’re synthesizing the stuff that yields biological life and viruses, we’re asking you to screen to see whether it is dangerous in some way. That seems like a reasonable thing for society to insist upon.”
Jacob Swett retweeted
In case you missed it: our Executive Director, @JacobSwett, and several GlycolISER grantees were featured in Vox about their efforts to evaluate glycols as a potential pandemic countermeasure.
Learn more about this exciting work⬇️: vox.com/future-perfect/48806…
Jacob Swett retweeted
At @IFP, we’ve spent the past 3 years thinking about all the different ways the US government & philanthropy fund R&D.
Until now, R&D funders haven’t had a systematic way to match the innovation problem to the right funding tool.
We built THE ATLAS OF INNOVATION to fill that gap.
atlasofinnovation.org
Alongside @UChi_MSA, we’ve boiled down thousands of hours of research into a handful of questions covering how much the R&D funder knows about:
- the problem they want to solve
- the solution it should have
- the team that should build the solution
Why the Atlas matters:
The US government spends close to $200 billion every year on R&D. And after the Anthropic and OpenAI IPOs, there will be hundreds of billions of dollars in new philanthropic giving.
Choosing the correct funding approach to the social problems they’re trying to solve will mean the difference between success and failure.
For example, NSF research grants have helped seed breakthroughs from MRI machines to search engines, but grants aren’t built to deliver the kind of industrial speed and scale that a project like Operation Warp Speed required.
Picking the wrong funding approach can leave programs behind schedule, over budget, or without anything to show for all the money they spent.
How we built the Atlas:
1. We began by creating a matrix of dozens of considerations that a thoughtful policymaker or funder would ideally weigh before deciding how to fund a project.
2. We looked at every major funding approach, from grants to R&D tax credits to advance market commitments, analyzing when they work well and when they fail to meet the mission.
3. We spent months deep in the weeds of contract theory and incentive design, looking at historical examples and the state-of-the-art research in innovation economics.
4. We then worked to turn that research into a tool that time-strapped policymakers and philanthropic funders could rely on at the start of an innovation funding cycle.
5. Three years later, we are launching just that: a new (and visually stunning) website to help funders decide how to best incentivize innovation. And all they have to know… is what they currently know about their innovation goal! The Atlas takes care of the rest.
How to navigate the Atlas:
Answer questions about your goal to find the funding approach aligned with the information you have.
Each funding mechanism has its purpose for particular technologies and specific moments in development.
There shouldn’t be an ARPA for every field, just like we don’t need a prize or AMC for every innovation. The Atlas helps you navigate those tradeoffs.
Thanks to Camus, the boulder & the absurd get all the attention.
I prefer Stephen Fry's take: just as Sisyphus believed he could escape death (and did!), he believes he'll complete this and be free.
It's a story of cleverness & tenacity of humanity against the 'natural order'.
Jacob Swett retweeted
We live in a post-smallpox world, and it's an incredible thing that we do not appreciate nearly enough.
jassipannu.substack.com/p/pa…
Jacob Swett retweeted
Three disease outbreaks. Three countries. Three epidemics prevented.
Last year El Salvador, Gabon and Thailand contained outbreaks of malaria, mpox and cholera before they spiraled into epidemics. In a new video, we hear from the health care workers involved about how they acted quickly to stop diseases from spreading using the 7-1-7 target for outbreak detection and response and saved lives.
You can read the full stories in our new Epidemics That Didn’t Happen report, launched today at #WHA79: etdh.resolvetosavelives.org/…





























